• 10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand

    Bio-IT World | At the 44th Annual J.P. Morgan Healthcare Conference, 10x Genomics announced a strong ending to 2025. With great anticipation for 2026, 10x Genomics remains centered on their mission on accelerating understanding of biology to advance human health, particularly in the single-cell and spatial biology areas.

    Jan 14, 2026

  • Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch

    Bio-IT World | Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights.

    Jan 13, 2026

  • PacBio at JPM 2026: Clinical Momentum and SPRQ-Nx Economics

    Bio-IT World | PacBio president Christian Henry presented at the 44th Annual J.P. Morgan Healthcare Conference with strong fourth quarter growth, breakthrough clinical adoption, and economics that position long-read sequencing as competitive with short reads.

    Jan 13, 2026

  • Oxford Nanopore at JPM 2026: Passing the Baton on a 20-Year Journey

    Bio-IT World | Gordon Sanghera, CEO, presented on behalf of Oxford Nanopore Technologies at the 44th Annual J.P. Morgan Healthcare Conference this week in San Francisco. In what he described as his final appearance at JPM as CEO, Sanghera reflected on 20 years of building a company around single-molecule electronic sensing while outlining a growth trajectory that saw the company exceed expectations in 2025.

    Jan 12, 2026

  • NVIDIA Bets Big on AI-Driven Drug Discovery, Physical AI, and a $1 Billion Eli Lilly Partnership

    Bio-IT World | NVIDIA is making a massive push into healthcare and life sciences, announcing a landmark five-year, $1 billion strategic partnership with pharmaceutical giant Eli Lilly alongside major expansions of its biological AI platform at the 2026 J.P. Morgan Healthcare Conference.

    Jan 12, 2026

  • TechBio Survey Shows a Mixed Industry Outlook, Claude Gaining Ground, More Machine Learning

    Bio-IT World | The Bits in Bio Slack-first community has released its fourth annual State of TechBio survey results. Year over year findings include a jump in Claude usage, an increase in daily machine learning work, and a serious cooling of the “Very bullish" sentiment across the broader biotech market.

    Jan 9, 2026